Karyopharm Therapeutics is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.09 – an increase of 11.65% over the previous week. Karyopharm Therapeutics employs 279 staff and has a trailing 12-month revenue of around $145.2 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.09 |
|---|---|
| 52-week range | $3.51 - $18.00 |
| 50-day moving average | $5.95 |
| 200-day moving average | $10.27 |
| Wall St. target price | $48.64 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-13.95 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.36 from 2025-05-02
| 1 week (2025-04-29) | 15.91% |
|---|---|
| 1 month (2025-04-07) | 82.18% |
| 3 months (2025-02-07) | 1,066.40% |
| 6 months (2024-11-07) | 734.28% |
| 1 year (2024-05-07) | 569.09% |
|---|---|
| 2 years (2023-05-05) | -81.89% |
| 3 years (2022-05-06) | 91.2 |
| 5 years (2020-05-06) | 288.6 |
| Revenue TTM | $145.2 million |
|---|---|
| Gross profit TTM | $139.2 million |
| Return on assets TTM | -36.88% |
| Return on equity TTM | -891.05% |
| Profit margin | -52.62% |
| Book value | $-22.11 |
| Market Capitalization | $63.1 million |
TTM: trailing 12 months
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Karyopharm Therapeutics's shares were split on a 1:15 basis on 25 February 2025 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Karyopharm Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Karyopharm Therapeutics shares which in turn could have impacted Karyopharm Therapeutics's share price.
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $3.51 up to $18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.586. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .